(Q33650432)

28 July 2017

title

Recent developments in oral hypoglycemic agents (English)

1 reference

28 July 2017

Shinkai H

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

4

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

283-288

1 reference

Diabetes complications: why is glucose potentially toxic?

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Prevention and treatment of the complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Management of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

LONG-TERM OBSERVATIONS ON ORAL HYPOGLYCEMIC AGENTS IN DIABETES; THE EFFECT OF CARBUTAMIDE AND TOLBUTAMIDE

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Nine years' experience with tolbutamide in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Diabetes mellitus treated with chlorpropamide and tolbutamide. A four-year clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Hydroxyurea derivatives as hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

The sulfonylurea receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

The pharmacology of ATP-sensitive potassium channels

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Sulfonylurea receptors and mechanism of sulfonylurea action

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Glibenclamide-associated hypoglycaemia: a report on 57 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic beta-cells by stimulating Ca2+ influx

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

4-(trans-4-Methylcyclohexyl)-4-oxobutyric acid (JTT-608). A new class of antidiabetic agent.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2899%2901331-8

7 January 2021

10.1016/S1359-6446(99)01331-8

Identifiers

DOI

1 reference

28 July 2017

1 reference